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Effect of LDL cholesterol, statins 
and presence of mutations 
on the prevalence of type 2 
diabetes in heterozygous familial 
hypercholesterolemia
Elisenda Climent1, Sofía Pérez-Calahorra2, Victoria Marco-Benedí2, Nuria Plana3, Rosa 
Sánchez4, Emilio Ros5, Juan F. Ascaso6, Jose Puzo7, Fátima Almagro8, Carlos Lahoz9, 
Fernando Civeira2 & Juan Pedro-Botet1
Patients with heterozygous familial hypercholesterolemia (HeFH) have been reported to be less 
vulnerable to type 2 diabetes mellitus (T2DM), although the mechanism is unknown. The aims of the 
present study were to assess the effects of low density lipoprotein (LDL) cholesterol concentration 
and the presence of FH-causing mutations on T2DM prevalence in HeFH. Data were collected from 
the Dyslipidemia Registry of the Spanish Arteriosclerosis Society. Inclusion criteria were definite or 
probable HeFH in patients aged ≥18 years. T2DM prevalence in HeFH patients was compared with data 
of the general population. 1732 patients were included. The prevalence of T2DM was lower in patients 
with HeFH compared with the general population (5.94% vs 9.44%; OR: 0.606, 95% CI 0.486–0.755, 
p < 0.001). Risk factors for developing T2DM were male sex, age, body mass index, hypertension, 
baseline triglyceride levels and years on statin therapy. The prevalence of T2DM in HeFH patients 
was 40% lower than that observed in the general population. Gene mutations and LDL cholesterol 
concentrations were not risk factors associated with the prevalence of T2DM in patients with HeFH. The 
prevalence of T2DM in patients with HeFH was 40% lower than in the general population matched for 
age and sex.
Heterozygous familial hypercholesterolemia (HeFH), the most frequent monogenic disorder of human metab-
olism caused by some mutations in the genes that encode for the low-density lipoprotein (LDL) receptor, apoli-
poprotein (apo) B, proprotein convertase subtilisin/kexin-type 9 (PCSK9) or apo E1, 2, entails an increased risk of 
premature cardiovascular disease2.
Patients with HeFH had been reported to be less vulnerable to type 2 diabetes mellitus (T2DM) compared to 
the general population3. More recently, Besseling et al. in a cross-sectional study found the prevalence of T2DM 
to be 50% lower in HeFH patients compared to unaffected relatives4. One of the mechanisms suggested to explain 
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this finding lies in potential decreased cholesterol uptake by pancreatic β cells in HeFH5. This lower T2DM 
risk contrasts with the fact that most HeFH patients are treated with high doses of potent statins which exert a 
dose-dependent diabetogenic effect6, 7. The molecular pathways that may be involved in the resistance to T2DM 
in HeFH and the statin-related T2DM have not been studied in depth in humans. Suggested mechanisms include 
defects in insulin signaling, pancreatic β -cell function and reduced glucose uptake in adipocytes throughout the 
glucose transporter-4 (GLUT4) pathway8. The potential effect of LDLR mutations or LDL cholesterol concen-
tration on these anti-diabetogenic and pro-diabetogenic effects of HeFH and statins, respectively, are unknown.
The cholesterol-lowering effect of statin therapy is mainly due to the inhibition of 3-hydroxy- 
3-methylglutaryl-CoA reductase, a key enzyme in cholesterol synthesis that induces a reduction in intracellular 
cholesterol content and a subsequent increase in LDL receptor expression in different tissues and the promotion 
of transmembrane cholesterol transport9, the primary altered mechanism in FH10. If intracellular cholesterol 
uptake via the LDL receptor is involved in the pathogenesis of T2DM, then it would explain the hypothetical 
protection from diabetes in HeFH patients, but only in those with genetic defects affecting LDL receptor uptake, 
in contrast to the hypothesis that the protection would be dependent on the high plasma LDL-cholesterol con-
centrations observed in HeFH. Hence, the aims of the present study were to assess the prevalence of T2DM in 
HeFH patients of the Dyslipidemia Registry of the Spanish Arteriosclerosis Society, and evaluate the impact of 
mutations in the LDLR, APOB and PCSK9 genes, baseline LDL cholesterol concentration and duration of statin 
treatment on T2DM prevalence in this population.
Research Design and Methods
Study population. The Dyslipidemia Registry of the Spanish Arteriosclerosis Society was created at the 
end of 2013 as an active on-line registry in which 50 certified Lipid Units distributed throughout Spain enter 
cases with different primary hyperlipidemias. These Lipid Units are the centers in the Spanish National Health 
Service to which most cases of primary hyperlipidemias are referred for diagnosis and treatment. The registry 
was approved by a central ethics committee to include anonymous clinical data (Comité Ético de Investigación 
Clínica de Aragón, Zaragoza, Spain) in accordance with the ethical guidelines of the 1975 Declaration of Helsinki. 
Patients did not have to complete an informed consent form as the data were obtained from an official national 
registry. Minimum data for the inclusion of cases in the registry are: age, sex, smoking status, personal history 
of hypertension, diabetes and cardiovascular disease with age at the first event, body mass index (BMI), waist 
circumference, total cholesterol, LDL cholesterol, triglycerides and high-density lipoprotein (HDL) cholesterol 
without lipid-lowering treatment, and clinical diagnosis. Cardiovascular disease in the registry is defined as: 
coronary heart disease (myocardial infarction, acute coronary syndrome with stenosis >50% of a main coronary 
artery and coronary revascularization), stroke (ischemic and hemorrhagic), aortic aneurysm and lower limb 
ischemia (intermittent claudication with ankle/brachial index <0.90 or revascularization of lower limb arteries). 
T2DM is defined in the presence of fasting blood glucose >125 mg/dL or use of blood glucose-lowering drugs.
Inclusion criteria in the present study were: complete minimum data for the registry, plus information on 
family history of hypercholesterolemia and premature cardiovascular disease; personal history of tendon xantho-
mas and presence of arcus cornealis before the age of 45; genetic study of LDLR, APOB and PCSK9 genes; age at 
statin onset; and age at T2DM diagnosis. Only subjects with probable (6–8 points) or definite (>8 points) HeFH 
according to the Dutch Lipid Clinic Network criteria10 and age ≥18 years were finally included. The diagnosis of 
homozygous FH (HoFH) was an exclusion criterion.
Of the 2,475 cases with the clinical diagnosis of genetic hypercholesterolemia included in the registry, 1,732 
diagnosed of HeFH with Dutch Lipid Clinic Network (DLCN) criteria ≥6 points and complete data were finally 
included. Reasons for exclusion from the analysis were HoFH or DLCN <6 points and lack of data on genetic 
analysis, among others.
The prevalence of T2DM was analyzed according to a probable or definite diagnosis of HeFH, the presence 
of a genetic mutation or the gene involved. Furthermore, T2DM prevalence in HeFH patients was compared 
with data of the general population matched for age and sex from the Di@bet.es Study. The Di@bet.es Study is a 
national, cross-sectional, population-based survey conducted in 2009–10 in a representative random sample of 
the Spanish population11.
Blood specimens were collected after an overnight (>10 h) fast and processed for laboratory analyses the same 
day. Serum total cholesterol, triglycerides and HDL cholesterol levels were measured locally using enzymatic 
methods. Serum LDL cholesterol concentration was calculated using the Friedewald formula.
DNA was isolated from whole blood using standard methods and screening for LDLR, APOB and PCSK9 
mutations was carried out using the Lipochip Platform (Progenika Biopharma S. A., Bilbao, Spain). The platform 
consists of two consecutive steps: the first is LIPOchip® microarray analysis for the detection of the most fre-
quent Spanish point mutations in the LDLR gene and in the APOB exon 26, as well as CNVs in LDLR. When the 
LIPOchip® microarray yielded a negative result (no mutation is found), the LDLR, APOB (binding domain) and 
PCSK9 gene coding sequences, exon-intron boundaries, and short proximal intronic sequences were sequenced 
with a GS Junior system (Roche Diagnostics Corporation, Basel, Switzerland)12.
Statistical analysis. Data were expressed as mean ± standard deviation for parametric variables and as 
median ± interquartile range for non-parametric quantitative variables. The Mann-Whitney U test was used for 
comparison between groups; quantitative variables were shown as % (n) and chi-square test was applied for 
qualitative variables between groups. Logistic regression analysis including sex, age, BMI, smoking status, hyper-
tension, tendon xanthomas, baseline LDL and HDL cholesterol and triglyceride concentrations, genetic diagnosis 
and statin therapy duration was applied to evaluate factors independently associated with the presence of T2DM 
in HeFH patients. A two-sided p value < 0.05 was considered statistically significant. Statistical analysis was cal-
culated with SPSS (version 19.0 for Windows; SPSS, Chicago, IL).
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Results
One thousand, seven hundred and thirty-two patients were included (354 with probable and 1,378 with definite 
HeFH) (Fig. 1). No differences were found between groups in terms of gender, cardiovascular disease prevalence 
and HDL cholesterol concentration. As expected because of the DLCN definition, total cholesterol and LDL 
cholesterol concentrations were higher, and the presence of tendon xanthomas more common in definite than in 
probable HeFH. In contrast, the prevalence of T2DM and variables associated with the metabolic syndrome and 
diabetes i.e. age, BMI, waist circumference, triglycerides, glucose and prevalence of hypertension were higher in 
the probable HeFH group than in definite HeFH. Subjects with definite HeFH had begun statin therapy 7 years 
earlier than probable HeFH (Table 1). A total of 103 (5.9%) HeFH were diagnosed of T2DM. The characteristics 
of subjects with and without T2DM are presented in Table 2. Diabetic patients were older and presented higher 
BMI, waist circumference, triglycerides, glycosylated hemoglobin, cardiovascular disease and hypertension prev-
alence than non-diabetics. HDL cholesterol was higher and a positive genetic diagnostic test was more common 
in non-diabetics than in diabetics. The number of years under statin treatment was higher in diabetics than in 
non-diabetics (Table 2).
The overall and divided-by-age group gender and genetic diagnosis prevalence of T2DM in HeFH with the 
odds ratios (OR) compared with the prevalence of the age- and gender-adjusted Spanish population are shown in 
Table 3. T2DM was more common in males than in females and increased with age in HeFH and in the general 
population. However, T2DM was significantly less frequent among HeFH, 5.94% versus 9.44% in the general 
Figure 1. Study flow diagram. HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial 
hypercholesterolemia; DLCN, Dutch Lipid Clinic Network.
Characteristics Probable FH N = 354 Definite FH N = 1,378 P
Men, % (n) 50.0 (177) 48.9 (674) 0.715
Age, years 56.0 (49.0–64.5) 50.0 (38.0–60.0) <0.001
Body mass index, kg/m2 26.7 (22.5–28.6) 26.2 (24.0–28.9) 0.006
Waist circumference, cm 93.0 (84.5–99.0) 90.0 (78.0–97.0) <0.001
Total cholesterol, mg/dL 300 (272–333) 340 (298–395) <0.001
Triglycerides, mg/dL 143 (99.5–194) 105 (75.0–143) <0.001
HDL cholesterol, mg/dL 54.0 (46.5–64.5) 53.0 (44.0–64.0) 0.753
LDL cholesterol, mg/dL 213 (190–251) 260 (216–316) <0.001
Glucose, mg/dL 91.0 (84.5–97.5) 89.0 (81.0–98.0) 0.051
Tendon xanthomas, % (n) 3.3 (12) 35.2 (485) <0.001
Cardiovascular disease, % (n) 11.9 (42) 13.4 (185) 0.489
Hypertension, % (n) 26.4 (93) 17.7 (244) <0.001
Diabetes, % (n) 9.1 (32) 5.2 (71) 0.006
Age at diabetes diagnosis, years 54.0 (50.8–60.0) 52.5 (46.5–60.3) 0.563
Age at statin onset, years 48.3 (37.0–56.0) 41.0 (31.0–51.0) <0.001
Statin therapy, years 5.0 (2.0–11.0) 7.0 (3.0–13.0) <0.001
Table 1. Demographic and clinical characteristics of heterozygous familial hypercholesterolemia patients. 
Values are expressed as median (interquartile range) for continuous variables and percentage (n) for categorical 
variables. HDL denotes high-density lipoprotein; LDL, low-density lipoprotein.
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population (OR: 0.606, 95% CI 486–0.755, p < 0.001). This difference was also present when only HeFH with 
a positive genetic diagnosis (OR: 0.438, 95% CI 0.323–0.593, p < 0.001) were considered.T2DM protection in 
HeFH was similar in all age groups and in both genders, but reached statistical significance only in older groups, 
owing to the low T2DM prevalence in subjects under 46 years of age (Table 3). Subjects with a functional muta-
tion in candidate genes were older, had higher BMI, waist circumference, triglyceride and glucose concentrations, 
and a higher prevalence of hypertension and T2DM than HeFH without mutations (Supplementary Table). On 
the other hand, no differences were observed in the prevalence of T2DM when patients were separated into dif-
ferent subgroups according to LDL-cholesterol concentrations (Fig. 2).
Risk factors for HeFH patients developing T2DM are presented in Table 4 for the whole HeFH group and in 
Table 5 for patients with a positive genetic diagnosis. Male sex, BMI, hypertension and years on statin therapy 
were independently associated with the presence of T2DM in both groups. These risk factors could account 
for up to 26% of the variability in presenting T2DM (Table 4). Other factors such as age, BMI, smoking status, 
xanthomas, baseline LDL, HDL cholesterol and triglyceride concentrations did not reach statistical significance.
Finally, different regression models were applied to identify the association of a pathogenic mutation in LDLR, 
APOB or PCSK9 in the presence of T2DM. None of the models with different adjustments showed any significant 
association of a positive genetic diagnosis with T2DM (Table 6).
Discussion
The prevalence of T2DM in HeFH patients in the present study was 5.9%, lower than the known 9.4% prevalence 
in the age and sex-adjusted Spanish population11. In a Dutch cohort, the prevalence of T2DM in HeFH patients 
was 1.75% compared to 2.93% in unaffected relatives4. This may be partially explained by younger age in the 
Dutch HeFH cohort, more than one decade, compared to our population and the different criteria used in the 
diagnosis of T2DM between studies, only auto-reported in the Dutch cohort4. Nevertheless, our study confirms 
the Dutch results in a completely different population, showing that HeFH subjects present an approximately 50% 
lower T2DM risk than the general population. This T2DM protection has been questioned in favor of a role for 
cellular cholesterol metabolism in the pathogenesis of type 2 diabetes4, 5.
Besides this confirmatory information, several important conclusions can be drawn from our study. First, the 
LDL cholesterol concentration before the start of lipid-lowering treatment did not play a major role in T2DM 
protection in HeFH in our study. The lower risk of T2DM appeared in a large LDL cholesterol range, and the 
LDL cholesterol concentration did not significantly affect T2DM risk. Although there is in-vivo and ex-vivo evi-
dence showing that LDL concentration modulates insulin secretion and pancreatic β-cell survival13, large pro-
spective studies showed no significant effect of LDL cholesterol on T2DM risk, in contrast to the association 
with high triglycerides or low HDL cholesterol that has been repeatedly demonstrated14, 15. In human β cell islets, 
LDL overload lowered insulin secretion16 and diet-induced hypercholesterolemia also reduced insulin secretion 
in mice17; however, this diabetogenic effect of hypercholesterolemic diets has also been associated with satu-
rated fatty acid accumulation rather than with cholesterol16, 18. Second, in the present study, no differences were 
observed in T2DM prevalence according to the presence or absence of causative gene mutations responsible for 
HeFH. Our study is the first to include clinically-diagnosed patients and analyzed T2DM prevalence according 
to LDLR, APOB or PCSK9 mutations. Besseling et al. included HeFH only with a confirmed pathogenic muta-
tion, and found a dose-dependent association in HeFH subjects with LDLR negative mutations who had a lower 
T2DM prevalence than HeFH carriers of defective LDLR or APOB mutations, suggesting that the severity of the 
genetic defect plays a role in T2DM protection4. The implication of the LDL receptor in glucose homeostasis is 
Characteristics
Diabetes 
N = 103
No diabetes 
N = 1,629 P
Men, % (n) 58.3 (60) 48.6 (792) 0.057
Age, years 64 (55.0–69.0) 51.0 (40.0–60.0) <0.001
Body mass index, kg/m2 28.9 (25.3–33.3) 25.5 (22.8–28.4) <0.001
Waist circumference, cm 100 (92.0–108) 89.0 (80.0–96.0) <0.001
Total cholesterol, mg/dL 348 (291–395) 331 (292–384) 0.318
Triglycerides, mg/dL 189 (129–256) 106 (78.0–155) <0.001
HDL cholesterol, mg/dL 47.5 (35.0–59.0) 53.0 (45.0–64.0) <0.001
LDL cholesterol, mg/dL 255 (202–312) 253 (211–300) 0.960
HbA1c*, % 6.7 (6.2–7.4) 5.5 (5.3–5.9) <0.001
Tendon xanthomas, % (n) 32.0 (33) 28.7 (468) 0.487
Positive genetic diagnosis, % (n) 46.6 (48) 64.6 (1052) 0.005
Cardiovascular disease, % (n) 40.8 (42) 11.3 (184) <0.001
Hypertension, % (n) 64.1 (66) 16.7 (271) <0.001
Age at diabetes diagnosis, years 53.0 (48.0–60–0) —
Age at statin onset, years 51.5 (43.0–59.0) 42.0 (31.5–52.0) <0.001
Statin therapy, years 10.0 (6.0–17.0) 7.0 (2.5–12.0) <0.001
Table 2. Demographic and clinical characteristics of heterozygous familial hypercholesterolemia patients with 
or without diabetes. *Values refer to 87 (84.5%) diabetics and 410 (25.2%) non-diabetics.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 5596  | DOI:10.1038/s41598-017-06101-6
controversial, since the deleterious effect of cholesterol overload on insulin secretion by pancreatic β cells was 
similar in LDLR-/- knockout or wild-type mice19, and oxidized LDL, which does not use the LDL receptor, was 
found to be a major contributor to β cell dysfunction20. Furthermore, some FH-causing mutations seem to be 
associated with a higher T2DM risk21. In our study, the presence of any LDLR/APOB/PCSK9 mutation was less 
common in HeFH with than without T2DM; however, these differences disappeared after adjustment for con-
founders unrelated to LDL receptor function.
Third, the factors associated with the presence of T2DM in HeFH are the same as those present in the gen-
eral population, including statin use. The cluster of abnormalities closely associated with insulin resistance: high 
blood pressure, high triglycerides, low HDL cholesterol, increased BMI and older age22, are also strongly related 
to the presence of T2DM in HeFH, as previously described23. In this observational, cross-sectional study, we 
could not calculate whether the impact of T2DM risk factors is different in HeFH than in non-FH; however, we 
did have a close approximation for statin use as this information was available. Statin use preceded the diagnosis 
of T2DM in most cases and the risk associated with statin use was identical to that observed in statin trials after 
adjustment for insulin-resistance markers6, 7, 24.
Thus, if LDL cholesterol or LDL receptor function itself are not responsible for the T2DM protection in HeFH, 
which mechanisms are involved? Potential explanations have been previously put forward: the observational 
cross-sectional design without power to establish causality; the possibility of unexplored potential confounders; 
a healthier lifestyle after receiving the diagnosis of HeFH; or a shorter life-expectancy in patients with HeFH and 
18–45 years 46–60 years >60 years Total
Men
General 
population, N/
Total (%)
14/909 (1.54) 69/578 (11.9) 163/687 (23.7) 246/2174 (11.3)
HeFH, N/Total 
(%) 2/337 (0.59) 23/338 (6.80) 35/178 (19.7) 60/853 (7.03)
Odds ratio (95% 
CI) 0.382 (0.086–1.688) 0.538 (0.329–0.881) 0.787 (0.523–1.185) 0.593 (0.442–0.796)
P 0.261 0.012 0.272 <0.001
HeFH 
mutation+, N/
Total (%)
2/246 (0.81) 15/188 (7.98) 13/103 (12.6) 30/537 (5.59)
Odds ratio (95% 
CI) 0.524 (0.118–2.231) 0.639 (0.356–1.147) 0.478 (0.263–0.870) 0.470 (0.319–0.694)
P 0.545 0.141 0.010 <0.001
Women
General 
population, N/
Total (%)
9/1222 (0.74) 54/818 (6.60) 170/858 (19.8) 233/2898 (8.04)
HeFH, N /Total 
(%) 2/277 (0.72) 18/318 (5.66) 23/285 (8.07) 43/880 (4.89)
Odds ratio (95% 
CI) 0.980 (0.211–4.562) 0.849 (0.489–1.471) 0.355 (0.225–0.562) 0.588 (0.421–0.821)
P 0.979 0.684 <0.001 0.002
HeFH 
mutation+, N/
Total (%)
2/221 (0.90) 6/185 (3.24) 10/157 (6.37) 18/563 (3.20)
Odds ratio (95% 
CI) 1.455 (0.359–5.093) 0.508 (0.222–1.164) 0.287 (0.150–0.549) 0.387 (0.239–0.627)
P 0.597 0.087 <0.001 <0.001
All
General 
population, N/
Total (%)
23/2131 (1.08) 123/1396 (8.81) 333/1545 (21.6) 479/5072 (9.44)
HeFH, N /Total 
(%) 4/614 (0.65) 41/656 (6.25) 58/463 (12.5) 103/1733 (5.94)
Odds ratio (95% 
CI) 0.601 (0.207–1.744) 0.689 (0.478–0.995) 0.521 (0.386–0.704) 0.606 (0.486–0.755)
P 0.343 0.046 <0.001 <0.001
HeFH 
mutation+, N/
Total (%)
4/467 (0.86) 21/373 (5.63) 23/260 (8.85) 48/1100 (4.36)
Odds ratio (95% 
CI) 0.791 (0.273–2.300) 0.617 (0.383–0.995) 0.353 (0.226–0.551) 0.438 (0.323–0.593)
P 0.667 0.046 <0.001 <0.001
Table 3. Prevalence of type 2 diabetes in a reference population and in heterozygous familial 
hypercholesterolemia patients by sex and age.
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T2DM4 could be responsible for this observation. The HDL particle is also an unexplored potential protective fac-
tor of T2DM in HeFH25. In HeFH, HDL cholesterol is usually within normal range10, 26 and, in contrast with other 
dyslipidemias, HDL particle size and number are in antiatherogenic range27. Indeed, the Dutch HeFH patients 
were leaner, smoked less and had lower triglycerides than their unaffected relatives without a clear explanation, 
except for a healthier lifestyle associated with the diagnosis4. In our cohort of HeFH patients, the prevalence of 
hypertension, overweight, obesity and tobacco use was much lower than that observed in the Spanish general 
population28, 29. Altogether, these data suggest that environmental factors could be involved in this T2DM protec-
tion in these patients cared for in highly specialized lipid units. Actually, the reduction in BMI compared with the 
reference population could explain one third of the lower risk of T2DM30. A large case-control study is underway 
to try to answer these questions.
Our study has some limitations. In this respect, the number of HeFH with T2DM was relatively low, but the 
concurrence with previous data supports the T2DM protection. Our study was cross-sectional, and results other 
than prevalence should thus be taken with caution. The sample was composed of middle-aged men and women 
from a Mediterranean country, with traditionally lower coronary heart disease rates than other populations, 
albeit with a high prevalence of T2DM11. Furthermore, patients included in the Spanish Dyslipidemia Registry 
are treated with a standardized protocol promoting the use of high-intensity lipid-lowering treatment in highly 
Figure 2. Prevalence of type 2 diabetes mellitus in heterozygous familial hypercholesterolemic patients 
according to LDL-cholesterol concentrations.
Standard coeff. (β) Exp (B) 95% CI P R2
Sex, male 0.649 1.913 1.204–3.040 0.006
0.261
Age, years 0.050 1.052 1.030–1.074 <0.001
BMI, kg/m2 0.021 1.021 1.007–1.035 0.004
Hypertension, yes 1.522 4.582 2.834–7.407 <0.001
Triglycerides, mg/dL 0.002 1.002 1.001–1.003 0.001
Statin therapy, years 0.031 1.031 1.003–1.060 0.03
Table 4. Factors associated with the presence of type 2 diabetes mellitus in clinically-defined heterozygous 
familial hypercholesterolemia patients (≥6 DLCN points). DLCN denotes Dutch Lipid Clinic Network; BMI, 
body mass index. Independent variables included in the model: sex, age, BMI, smoking status, hypertension, 
tendon xanthomas, baseline LDL and HDL cholesterol and triglyceride concentrations, genetic diagnosis and 
statin therapy duration.
Standard coeff. (β) Exp (B) 95% CI p R2
Sex, male 0.713 2.041 1.081–3.853 0.028
0.195
BMI, kg/m2 0.018 1.018 1.003–1.034 0.022
Hypertension, yes 2.072 7.942 4.249–14.845 <0.001
Statin therapy, years 0.044 1.045 1.002–1.090 0.040
Table 5. Factors associated with the presence of type 2 diabetes mellitus in genetically-defined heterozygous 
familial hypercholesterolemia patients (with a pathogenic mutation in LDLR, APOB or PCSK9 genes). BMI 
denotes body mass index. Independent variables included in the model: sex, age, BMI, smoking status, 
hypertension, tendon xanthomas, baseline LDL and HDL cholesterol and triglyceride concentrations, genetic 
diagnosis and statin therapy duration.
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specialized Lipid Clinics; thus, the results cannot be easily extrapolated to other clinical settings. Finally, the 
observed prevalence of T2DM in HeFH could be underestimated since patients with HeFH are at increased risk 
for cardiovascular disease and some will have died before their inclusion in the Dyslipidemia Spanish registry. If 
HeFH was associated with T2DM, the possibility of early death from cardiovascular causes was even higher. On 
the other hand, T2DM prevalence increases with age and HeFH patients who died prematurely might have been 
less likely to develop T2DM; thus, an overestimation of T2DM in our cohort is also possible. In any event, the 
mean age of HeFH patients was around 55 years, and the prevalence of T2DM increased with age in both HeFH 
patients and in the general population.
Conclusions
In summary, the absolute prevalence of T2DM in patients with HeFH was 40% lower than that observed in the 
general population matched for age and sex. Risk factors independently associated with the presence of T2DM in 
subjects with HeFH were age, male sex, BMI, baseline triglycerides, hypertension and years of statin treatment. 
LDL cholesterol concentrations and the presence of mutations in FH-causing genes were not associated with the 
presence of T2DM in HeFH subjects.
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